Portra/E+ via Getty Images It takes time to turn around a large business, particularly when there are enough problems to create a 12-point to-do list, but Smith & Nephew (NYSE:SNN) is delivering on a lot of its targets and the market is taking notice. The shares have climbed over 35% since my last update, beating the broader med-tech sector, as well as peers/rivals like Stryker (SYK), Zimmer Biomet (ZBH), and Enovis (ENOV) with a combination of better than expected revenue and improving margins. It may  ...